Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Neurodevelopmental disorders

Lovastatin as fragile X therapy

Fragile X syndrome (FXS) is caused by loss of the fragile X mental retardation 1 gene product, a repressor of mRNA translation. It is thought that excessive protein synthesis downstream of metabotropic glutamate receptor 5 activation leads to many of the neuropsychiatric symptoms of FXS. The authors show that lovastatin, a widely prescribed cholesterol-lowering drug, can normalize protein synthesis in the hippocampus of a mouse model of FXS and prevent epileptogenesis. Although the effects of the drug on the neurocognitive phenotypes of these mice remain to be investigated, lovastatin could be a promising therapy for FXS.

ORIGINAL RESEARCH PAPER

  1. Osterweil, E. K. et al. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron 77, 243–250 (2013)

    CAS  Article  Google Scholar 

Download references

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Flight, M. Lovastatin as fragile X therapy. Nat Rev Neurosci 14, 156 (2013). https://doi.org/10.1038/nrn3459

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrn3459

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing